



04-15-02

1632

#22

la

4/23/02

EXPRESS MAIL NO.: EL 477 035 639 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kensil

Serial No.: 09/369,941

Group Art Unit: 1632

APR 17 2002

Filed: August 6, 1999

Examiner: M. Wilson

TECH CENTER 1600/2900

For: COMPOSITIONS OF CPG AND SAPONIN ADJUVANTS AND USES THEREOF Attorney Docket No.: 8449-156-999

**TRANSMITTAL OF REVOCATION AND  
POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST**

Commissioner of Patents and Trademarks  
Washington, DC 20231

S I R:


Pursuant to 37 C.F.R. § 1.36, Applicants submit herewith a Revocation and Power of Attorney that provides Pennie & Edmonds LLP with power of attorney in connection with the above-identified patent application.

Please direct all correspondence and telephone calls to Pennie & Edmonds LLP at the address indicated below.

Applicants do not believe there is a fee due in connection with this submission. However, should the Patent and Trademark Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: April 12, 2002

  
47,167  
Scott Warren (Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
Phone: (212) 790-9090

**For: Adriane Antler, Reg. No. 32,605**  
**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
Phone: (212) 790-9090



RECEIVED

APR 17 2002

TECH CENTER 1600/2900

Express Mail No.  
EL 477 035 639 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kensil

Serial No.: 09/369,941

Group Art Unit: 1632

Filed: August 6, 1999

Examiner: M. Wilson

For: COMPOSITIONS OF CPG AND SAPONIN  
ADJUVANTS AND USES THEREOF

Attorney Docket No.: 8449-156-999

**REVOCATION AND POWER OF ATTORNEY**  
**BY ASSIGNEE OF ENTIRE INTEREST**

Assistant Commissioner for Patents  
Washington, D.C. 20231

S I R :

Antigenics Inc., a Massachusetts corporation, having an address at 34 Commerce Way, Woburn, Massachusetts 01801, is the owner of the entire right, title and interest in, to and under the invention described and claimed in the above-identified patent application **by virtue of an assignment recorded on February 7, 2000, at Reel 010610, Frame 0875 and a merger with Aquila Biopharmaceuticals, Inc. (a copy of the Certificate of Merger of Aquila Biopharmaceuticals, Inc. into Antigenics Inc. is attached). The name change of the Assignee from Aquila Biopharmaceuticals, Inc. to Antigenics Inc. was recorded on March 26, 2002** (a copy of the Recordation Cover Sheet is attached). Antigenics Inc. hereby revokes all previous powers of attorney and appoints Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No.

33607), Gary S. Williams (Reg. No. 31066), Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), Alan Tenenbaum (Reg. No. 34939), Michael J. Lyons (Reg. No. 37,386), Garland T. Stephens (Reg. No. 37,242) and William J. Sipio (Reg. No. 34,514), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them its attorneys, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all future correspondence to Pennie & Edmonds LLP, located at 1155 Avenue of the Americas, New York, N.Y. 10036-2711, and direct all telephone calls to Pennie & Edmonds LLP at (212) 790-9090.

Date: April 8, 2002

Respectfully submitted,

By: 

Russell Herndon  
President  
Antigenics Inc.

State of Delaware  
Office of the Secretary of State

---

PAGE 1

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"AQUILA BIOPHARMACEUTICALS, INC.", A DELAWARE CORPORATION,  
WITH AND INTO "ANTIGENICS INC." UNDER THE NAME OF  
"ANTIGENICS INC.", A CORPORATION ORGANIZED AND EXISTING UNDER  
THE LAWS OF THE STATE OF MASSACHUSETTS, AS RECEIVED AND FILED IN  
THIS OFFICE THE THIRTY-FIRST DAY OF MAY, A.D. 2001, AT 2 O'CLOCK  
P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE  
NEW CASTLE COUNTY RECORDER OF DEEDS.



*Harriet Smith Windsor*  
Harriet Smith Windsor, Secretary of State

3398165 8100M

AUTHENTICATION: 1163848

010259992

DATE: 05-31-01

CERTIFICATE OF MERGER  
OF  
AQUILA BIOPHARMACEUTICALS, INC.  
(a Delaware corporation)  
INTO  
ANTIGENICS INC.  
(a Massachusetts corporation)  
which will be the surviving corporation  
(UNDER SECTION 252 OF THE GENERAL CORPORATION LAW  
OF THE STATE OF DELAWARE)

The undersigned corporation, organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify:

FIRST: That the name and state of incorporation of each of the constituent corporations of the merger is as follows:

<u>Name</u>	<u>State of Incorporation</u>
Aquila Biopharmaceuticals, Inc.	Delaware
Antigenics Inc.	Massachusetts

SECOND: That an agreement and plan of merger between the parties to the merger has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the requirements of Section 252 of the General Corporation Law of the State of Delaware.

THIRD: That the surviving corporation of the merger is Antigenics Inc.

FOURTH: That, by virtue of the merger, the Articles of Organization of Antigenics Inc. shall be the articles of organization of the surviving corporation.

FIFTH: That the executed agreement and plan of merger is on file at the Massachusetts office of the surviving corporation, located at 34-A Commerce Way, Woburn, MA 01801.

SIXTH: That a copy of the agreement and plan of merger will be furnished by the surviving corporation, on request and without costs, to any stockholder of any constituent corporation.

SEVENTH: That the surviving corporation agrees that it may be served with process in the State of Delaware in any proceeding for enforcement of any obligation of any constituent

corporation of the State of Delaware, as well as for enforcement of any obligation of the surviving corporation arising from the merger, including any suit or other proceeding to enforce the right of any stockholders as determined in appraisal proceedings pursuant to Section 262 of the General Corporation Law of the State of Delaware and irrevocably appoints the Secretary of State of the State of Delaware as its agent to accept service of process in any such suit or other proceedings and a copy of such process shall be mailed by the Delaware Secretary of State to: Antigenics Inc., 630 Fifth Avenue, Suite 2100, New York, New York.

*[Remainder of Page Intentionally Left Blank]*


IN WITNESS WHEREOF, Antigenics Inc. has caused this Certificate of Merger to be signed by its authorized officer, with effect as of the 31st day of May, 2001.

ANTIGENICS INC.

By: 

Name: Garo Admen

Title: President



Express Mail No.: EL 501 743 034 US

RECORDATION FORM COVER SHEET  
PATENTS ONLY

Attorney Docket Number  
8449-156-999

TO THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS  
Box Assignment  
Washington, DC 20231

Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

AQUILA BIOPHARMACEUTICALS, INC.

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: ANTIGENICS INC.

Address: 34 Commerce Way

Woburn, Massachusetts 01801

Country (if other than USA):

3. Nature of conveyance:

☐ Assignment

☒ Merger

☐ Security Agreement

☒ Change of Name

☐ Other

Execution Date:

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) 09/369,941

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom  
correspondence concerning document should be  
mailed:

PENNIE & EDMONDS LLP  
1155 Avenue of Americas  
New York, N.Y. 10036-2711

6. Number of applications  
and patents involved: 1


7. Total fee (37 CFR 3.41):.....\$ 40.00  
Please charge to the deposit account listed in Section 8.

8. Deposit account number:  
16-1150

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

By:  47,167  
Scott Warren Reg No.

Adriane M. Antler  
Name of Person Signing

32,605  
Reg. No.

  
Signature

March 26, 2002  
Date

Total number of pages (including cover sheet with duplicate): 13

Mail documents to be recorded with required cover sheet information to:  
Commissioner of Patents & Trademarks, Box Assignment  
Washington, D.C. 20231